Diagnostics and therapeutics: the CRISPR story continues The Lancet Microbe ++... ++

Diagnostics and therapeutics: the CRISPR story continues The Lancet Microbe https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(26)00072-8/fulltext?dgcid=raven_jbs_etoc_email Apr 2026 Volume 7Number 4 https://www.thelancet.com/journals/lanmic/issue/vol7no4/PIIS2666-5247(26)X2003-1 Safety, colonisation kinetics, transmissibility, and immune correlates of protection in healthy adults inoculated with Bordetella pertussis in England: a single-centre, open-label, phase 1, controlled human infection study Hans de Graaf, PhDa,b,c,d,∗ ∙ Diane F Gbesemete, PhDa,b,e,∗ ∙ Alison R Hill, PhDa,b,e,∗ ∙ Janeri Fröberg, PhDc,d ∙ Muktar M Ibrahim, PhDe ∙ Adam P Dale, PhDa,b,e ∙ et al. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00241-1/fulltext?dgcid=raven_jbs_etoc_feature_lanmic Safety, recovery, and pharmacodynamics of CRISPR–Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study Anders Østergaard Petersen, PhDa ∙ Birgitte Damholt, PhDa ∙ Mette Grove, PhDa ∙ Jonas Hink, PhDa ∙ Tamara Marotte-Hurbon, MSca ∙ Johan Söderqvist, MSca ∙ et al. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00185-5/fulltext?dgcid=raven_jbs_etoc_feature_lanmic